A large real-world analysis eases a lingering worry — that GLP-1 weight loss weakens bones — finding lower fracture rates with semaglutide in type 2 diabetes.
New research suggests oral GLP-1 drugs like orforglipron dial down eating for pleasure — not just hunger — by acting on the brain's reward system.
In 355,000 people, higher coffee intake was linked to sharply lower risks of cirrhosis, liver cancer, and liver-related death — with decaf working too.
A study of older adults with exceptional memory finds their gift can't be explained by lucky Alzheimer's-protective genes, pointing to other factors.
The new nonprescription tablet pairs acetaminophen and naproxen sodium for 12-hour pain relief — the first fixed-dose combo of the two sold over the counter.
JAK inhibitors raise shingles risk, so timing the vaccine matters. A randomized trial found a trade-off between a stronger vaccine response and faster arthritis relief.
Kobe University researchers mass-produced iPSC-derived γδ T cells that cut tumor weight by up to 88% in mice — a step toward cheaper, ready-made cell therapy.
A new analysis explains the paradox: GLP-1 drugs are cost-effective per patient, yet the sheer number of eligible people makes broad coverage financially daunting for insurers.
An algorithm hunting through human genes surfaced BRP, a natural peptide that curbed appetite in mice and pigs without the nausea seen with GLP-1 drugs.
Lab-grown human neurons show the protective APOE2 variant is better at repairing DNA damage and resisting the cellular aging linked to neurodegeneration.
Despite Phase 3 efficacy, Sanofi says its OX40 drug wouldn't meaningfully beat standard care — the latest setback for a once-promising class of immune drugs.
New Triumph trial data show 21–23% weight loss in patients with diabetes or heart disease, setting up a 2027 filing for Lilly's triple-hormone drug.